Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - SENORX INC | senorx_8k-102609.htm |
EXHIBIT 99.1
 |
PRESS RELEASE |
SENORX
APPOINTS JOHN T. BUHLER PRESIDENT AND CHIEF OPERATING OFFICER
IRVINE,
Calif., October 27 – SenoRx, Inc. (NASDAQ: SENO) today announced the
appointment of John T. Buhler to the newly created position of President and
Chief Operating Officer. Buhler, who currently serves as SenoRx’s
Senior Vice President and Chief Commercial Officer, joined the company in May
2008 as Vice President of International Sales and Business
Development. Previously Buhler served as President and Chief
Executive Officer at Ultrasonix Medical Corporation, a privately held
manufacturer of high-quality diagnostic ultrasound imaging equipment based in
British Columbia. Prior to his position at Ultrasonix, Buhler held
various positions at General Electric over a seven-year period, last serving as
Vice President and General Manager of GE’s Ultrasound Performance Technologies
Division.
Lloyd
Malchow, Chairman and Chief Executive Officer of SenoRx, said, ”John’s
appointment to the new post of President and Chief Operating Officer is another
step in our ongoing efforts to enhance the depth and breadth of our senior
management team. John’s extensive industry experience, demonstrated
leadership capabilities and proven track record of building growth-oriented
organizations in both large and small companies will help us further capitalize
on the significant opportunities for SenoRx as we continue to grow our business
globally.”
Malchow
continued, “I had the pleasure of working with John as a colleague when he was
CEO of Ultrasonix prior to joining our firm, and he has continued to demonstrate
the same strong skill set and leadership qualities at SenoRx that were readily
apparent in his previous management role. John’s contributions since
coming to SenoRx 18 months ago have been significant. Under his
leadership, SenoRx has greatly expanded its international market penetration and
he has been instrumental in building close strategic relationships with key
business partners. He has clearly emerged as a leader within our
company.”
About
SenoRx
SenoRx
(NASDAQ: SENO) develops, manufactures and sells minimally invasive medical
devices used by breast care specialists for the diagnosis and treatment of
breast cancer, including its EnCor® vacuum-assisted breast biopsy system and
Contura™ MLB catheter for delivering radiation to the tissue surrounding the
lumpectomy cavity following surgery for breast cancer. SenoRx’s field
sales organization serves over 2,000 breast diagnostic and treatment centers in
the United States and Canada. In addition, SenoRx sells several of
its products through distribution partners in more than 30 countries outside the
U.S. and Canada. The company’s line of breast care products includes biopsy
disposables, biopsy capital equipment, diagnostic adjunct products and
therapeutic disposables. SenoRx is developing additional minimally invasive
products for the diagnosis and treatment of breast cancer. For more
information, visit the company’s website at www.senorx.com.
| CONTACT: |
SenoRx,
Inc.
Lila
Churney, Director of Investor Relations
949.362.4800
ext.132
|